ventricular arrhythmias in dogs (part 1)

Since the Cardiac Arrhythmia Suppression Trial , which showed some dangerous effects of class I sodium channel blocking anti-arrhythmic drugs on patients with ischemic heart disease, class III drugs, especially new D-sota-lol-like drugs, have become a centre of interest for pharmacologists and cardiologists. We have been examining class III drugs for several years using canine arrhythmia models to characterize individual new drugs . New synthetic class III antiarrhythmic agents of Vaughan Williams’ classification inhibit cardiac potassium channels, but have no effect on the cardiac calcium and sodium channels. As a result of this effect, they prolong action potential duration as well as effective refractory period (ERP).We used canine automaticity ventricular arrhythmias following two-stage coronary ligation, digitalis and adrenaline administration , and canine reentry type arrhythmias, ie, the coronary ligation and reperfusion-induced ventricular arrhythmia model and programmed electrical stimulation (PES) -induced arrhythmia in dogs with ‘old’ (seven to 10 days) myocardial infarction. The drugs used were E-4031 , MS-551 , D-sotalol , sematilide , dofetilide and amiodarone , which has already been reported, and KCB 328. KCB 328 is a new D-sotalol derivative currently under preclinical evaluation (Figure 1). It’s your turn to find generic sildenafil online cialis professional to see how advantageous your shopping can be.

Effects of class III antiarrhythmic drugs on ventricular arrhythmias in dogs

Figure 1 Chemical structure of KCB 328